NIH panel refutes FDA’s claims of the benefits of coronaviru
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A panel of experts convened by the National Institutes of Health said on 2 August, there is “insufficient data” to show convalescent plasma works against the coronavirus, refuting claims made by US President Donald Trump and the head of the Food and Drug Administration.

The panel said it reviewed available data on the treatment and found nothing from “well-controlled, adequately powered randomized clinical trials that demonstrate the efficacy and safety of convalescent plasma” for the treatment of Covid-19.

It also said, “there was no difference in 7-day survival” for patients, contradicting FDA Commissioner Dr Stephen Hahn, who said the treatment resulted in a 35% improvement in survival.

“There are insufficient data to recommend either for or against the use of convalescent plasma for the treatment of COVID-19,” the panel said in a statement. “Convalescent plasma should not be considered standard of care for the treatment of patients with COVID-19.”

The FDA granted the treatment emergency authorization on Aug. 23, allowing U.S. health-care providers to use the plasma to treat suspected or confirmed infections in hospitalized patients.

The NIH panel said will continue to evaluate emerging clinical data on the use of convalescent plasma of Covid-19. It said “well-controlled, adequately powered randomized trials are needed to determine whether convalescent plasma is effective and safe.”

Source: https://www.cnbc.com/2020/09/01/nih-panel-refutes-fdas-claims-of-the-benefits-of-coronavirus-plasma-treatment.html
1 share
Like
Comment
Share